Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. A conference call and simultaneous webcast are scheduled for 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) that day.

Investors may join the live call by telephone with pre-registration or listen via the live audio webcast on the company’s Investors Events and Presentation page. A replay of the webcast will be available on the company website through December 10, 2025.

DUBLIN, Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here. Those interested in the live audio webcast of the conference call may access it by clicking here or visiting the Events and Presentation page under the Investors Section on Theravance Biopharma's website.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through December 10, 2025.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025-302594981.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma (TBPH) report Q3 2025 results?

Theravance Biopharma will report Q3 2025 results after market close on November 10, 2025.

What time is the TBPH conference call and webcast on November 10, 2025?

The conference call and webcast begin at 5:00 PM ET (2:00 PM PT / 10:00 PM GMT) on November 10, 2025.

How can investors access the TBPH live webcast for the Q3 2025 update?

Investors can access the live audio webcast via the company’s Investors Events and Presentation page or the provided webcast link.

Is there a replay available for the Theravance Biopharma Q3 2025 webcast?

Yes. A replay will be available on the company website through December 10, 2025.

Do I need to pre-register to join the TBPH conference call by phone?

Yes. Telephone participants are asked to pre-register using the company’s provided conference registration link.

Where will TBPH publish accompanying materials for the November 10, 2025 presentation?

Accompanying materials and the webcast link will be posted on the Theravance Biopharma Investors Events and Presentation page.